BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 29400697)

  • 1. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
    Wang CW; Yang LY; Chen CB; Ho HC; Hung SI; Yang CH; Chang CJ; Su SC; Hui RC; Chin SW; Huang LF; Lin YY; Chang WY; Fan WL; Yang CY; Ho JC; Chang YC; Lu CW; Chung WH;
    J Clin Invest; 2018 Mar; 128(3):985-996. PubMed ID: 29400697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
    Jacobsen A; Olabi B; Langley A; Beecker J; Mutter E; Shelley A; Worley B; Ramsay T; Saavedra A; Parker R; Stewart F; Pardo Pardo J
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013130. PubMed ID: 35274741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
    Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting Lesional Granulysin Levels for Rapid Diagnosis of Cytotoxic T lymphocyte-Mediated Bullous Skin Disorders.
    Chen CB; Kuo KL; Wang CW; Lu CW; Chung-Yee Hui R; Lu KL; Chang WC; Chen WT; Yun F; Teng YC; Lee HE; Lin JY; Ho HC; Chi MH; Yu-Wei Lin Y; Chang CJ; Lin Y; Ku CL; Hung SI; Chang YC; Chung WH;
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1327-1337.e3. PubMed ID: 33039642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis.
    Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF
    J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.
    Zhang S; Tang S; Li S; Pan Y; Ding Y
    J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955
    [No Abstract]   [Full Text] [Related]  

  • 8. Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tian CC; Ai XC; Ma JC; Hu FQ; Liu XT; Luo YJ; Tan GZ; Zhang JM; Li XQ; Guo Q; Zeng FQ; Shi ZR; Wang L
    Ann Allergy Asthma Immunol; 2022 Sep; 129(3):360-365.e1. PubMed ID: 35598882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic TNF-α Inhibitors for Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis.
    Cao J; Zhang X; Xing X; Fan J
    Dermatol Ther (Heidelb); 2023 Jun; 13(6):1305-1327. PubMed ID: 37178320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.
    So N; Leavitt E; Aleshin M; Worswick S
    Dermatol Ther; 2018 Sep; 31(5):e12684. PubMed ID: 30175438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies.
    Lin CC; Chen CB; Wang CW; Hung SI; Chung WH
    Expert Rev Clin Immunol; 2020 Apr; 16(4):373-387. PubMed ID: 32154748
    [No Abstract]   [Full Text] [Related]  

  • 12. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit.
    Houschyar KS; Tapking C; Borrelli MR; Nietzschmann I; Puladi B; Ooms M; Rein S; Houschyar M; Duscher D; Maan ZN; Reumuth G; Branski LK; Modabber A; Kluwig D; Schmitt L; Philipp-Dormston WG; Yazdi AS; Siemers F
    J Wound Care; 2021 Jun; 30(6):492-496. PubMed ID: 34121430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
    Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI
    J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
    Chen CB; Wang CW; Chung WH
    Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
    Chung WH; Hung SI
    J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis.
    Olsson-Brown A; Yip V; Ogiji ED; Jolly C; Ressel L; Sharma A; Bergfeld W; Liu X; Khirwadkar N; Bellon T; Dickinson A; Ahmed S; Langton A; Watson R; Pirmohamed M; Carr DF
    J Invest Dermatol; 2023 Jun; 143(6):1023-1030.e7. PubMed ID: 36581093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
    Schneider JA; Cohen PR
    Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI; Yang JY; Su SC; Huang SP; Wei CY; Chin SW; Chiou CC; Chu SC; Ho HC; Yang CH; Lu CF; Wu JY; Liao YD; Chen YT
    Nat Med; 2008 Dec; 14(12):1343-50. PubMed ID: 19029983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.